Hidradenitis
10
0
2
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
30.0%
3 terminated out of 10 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Anifrolumab for Hidradenitis Suppurativa
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
HIDRAdenitis Suppurativa and HEART Disease
HidraWear Study for Hidradenitis Suppurativa Wounds
Wound Etiology and Healing Study
Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact
Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life